Literature DB >> 21054774

Rationale for triple-combination therapy for management of high blood pressure.

Alan H Gradman1.   

Abstract

The goals of antihypertensive therapy include optimal reduction in blood pressure (BP) while providing a favorable tolerability profile that promotes long-term adherence to treatment. For most patients with hypertension, these treatment goals cannot be achieved with monotherapy. When instituted early, however, combination therapy results in more rapid control of BP. This approach may facilitate improvements in long-term clinical outcomes, compared with more traditional and time-consuming stepped care and add-on algorithms for the management of hypertension. This review summarizes the rationale behind combination therapy, specifically triple-combination therapy, and discusses which combinations are most likely to result in better BP control, fewer side effects, and reduced risk of target organ damage. Supporting evidence from recent triple-combination therapy trials also is included in the review. Finally, the role of single-pill (fixed-dose) combination therapy in enhancing patient adherence is also discussed.
© 2010 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21054774      PMCID: PMC8816471          DOI: 10.1111/j.1751-7176.2010.00360.x

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  36 in total

1.  Effects of a structured treatment algorithm on blood pressure goal rates in both stage 1 and stage 2 hypertension.

Authors:  J M Neutel; D H G Smith; T N Silfani; Y Lee; M A Weber
Journal:  J Hum Hypertens       Date:  2006-04       Impact factor: 3.012

2.  Triple fixed-dose combination therapy: back to the past.

Authors:  Henry R Black
Journal:  Hypertension       Date:  2009-05-26       Impact factor: 10.190

3.  Combination therapy in hypertension.

Authors:  Alan H Gradman; Jan N Basile; Barry L Carter; George L Bakris
Journal:  J Am Soc Hypertens       Date:  2010 Jan-Feb

4.  Optimisation of antihypertensive treatment by crossover rotation of four major classes.

Authors:  J E Dickerson; A D Hingorani; M J Ashby; C R Palmer; M J Brown
Journal:  Lancet       Date:  1999-06-12       Impact factor: 79.321

5.  A simplified approach to the treatment of uncomplicated hypertension: a cluster randomized, controlled trial.

Authors:  Ross D Feldman; Guang Y Zou; Margaret K Vandervoort; Cindy J Wong; Sigrid A E Nelson; Brian G Feagan
Journal:  Hypertension       Date:  2009-02-23       Impact factor: 10.190

6.  Based treatment algorithm for essencial hypertension with olmesartan medoxomil.

Authors:  Marco Antônio Mota Gomes; Audes Diógenes de Magalhães Feitosa; Wille Oigman; José Márcio Ribeiro; Emílio Hideyuki Moriguchi; José Francisco Kerr Saraiva; Dalton Bertolim Précoma; Artur Beltrame Ribeiro; Celso Amodeo; Andréa Araujo Brandão
Journal:  Arq Bras Cardiol       Date:  2008-09       Impact factor: 2.000

7.  Triple antihypertensive therapy with amlodipine, valsartan, and hydrochlorothiazide: a randomized clinical trial.

Authors:  David A Calhoun; Yves Lacourcière; Yann Tong Chiang; Robert D Glazer
Journal:  Hypertension       Date:  2009-05-26       Impact factor: 10.190

8.  ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses.

Authors:  Jackson T Wright; Jeffrey L Probstfield; William C Cushman; Sara L Pressel; Jeffrey A Cutler; Barry R Davis; Paula T Einhorn; Mahboob Rahman; Paul K Whelton; Charles E Ford; L Julian Haywood; Karen L Margolis; Suzanne Oparil; Henry R Black; Michael H Alderman
Journal:  Arch Intern Med       Date:  2009-05-11

Review 9.  The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2--therapy.

Authors:  Nadia A Khan; Brenda Hemmelgarn; Robert J Herman; Chaim M Bell; Jeff L Mahon; Lawrence A Leiter; Simon W Rabkin; Michael D Hill; Raj Padwal; Rhian M Touyz; Pierre Larochelle; Ross D Feldman; Ernesto L Schiffrin; Norman R C Campbell; Gordon Moe; Ramesh Prasad; Malcolm O Arnold; Tavis S Campbell; Alain Milot; James A Stone; Charlotte Jones; Richard I Ogilvie; Pavel Hamet; George Fodor; George Carruthers; Kevin D Burns; Marcel Ruzicka; Jacques DeChamplain; George Pylypchuk; Robert Petrella; Jean-Martin Boulanger; Luc Trudeau; Robert A Hegele; Vincent Woo; Phil McFarlane; Michel Vallée; Jonathan Howlett; Simon L Bacon; Patrice Lindsay; Richard E Gilbert; Richard Z Lewanczuk; Sheldon Tobe
Journal:  Can J Cardiol       Date:  2009-05       Impact factor: 5.223

10.  Use of an olmesartan medoxomil-based treatment algorithm for hypertension control.

Authors:  Joel M Neutel; David H G Smith; Michael A Weber; Antonia C Wang; Harvey N Masonson
Journal:  J Clin Hypertens (Greenwich)       Date:  2004-04       Impact factor: 3.738

View more
  24 in total

1.  Short Term Safety and Tolerability of a Fixed Dose Combination of Olmesartan, Amlodipine and Hydrochlorothiazide.

Authors:  J C Mohan; Rishi Jain; Vijay Chamle; Amit Bhargava
Journal:  J Clin Diagn Res       Date:  2015-08-01

Review 2.  Aliskiren, amlodipine and hydrochlorothiazide triple combination for hypertension.

Authors:  Eric Judd; Edgar A Jaimes
Journal:  Expert Rev Cardiovasc Ther       Date:  2012-03

3.  Fixed and Low-Dose Combinations of Blood Pressure-Lowering Agents: For the Many or the Few?

Authors:  Massimo Leggio; Augusto Fusco; Claudia Loreti; Giorgio Limongelli; Maria Grazia Bendini; Andrea Mazza; Antonio Frizziero; Daniele Coraci; Luca Padua
Journal:  Drugs       Date:  2019-11       Impact factor: 9.546

4.  Physiologically Based Pharmacokinetic Modeling of Fimasartan, Amlodipine, and Hydrochlorothiazide for the Investigation of Drug-Drug Interaction Potentials.

Authors:  Su-Jin Rhee; Hyun A Lee; Soyoung Lee; Eunwoo Kim; Inseung Jeon; Im-Sook Song; Kyung-Sang Yu
Journal:  Pharm Res       Date:  2018-10-15       Impact factor: 4.200

Review 5.  Triple Combination Therapies Based on Olmesartan: A Personalized Therapeutic Approach to Improve Blood Pressure Control.

Authors:  Massimo Volpe; Caterina Santolamazza; Vittoria Mastromarino; Roberta Coluccia; Allegra Battistoni; Giuliano Tocci
Journal:  High Blood Press Cardiovasc Prev       Date:  2017-06-12

Review 6.  Triple-combination therapy in the treatment of hypertension: a review of the evidence.

Authors:  R Düsing; B Waeber; M Destro; C Santos Maia; P Brunel
Journal:  J Hum Hypertens       Date:  2017-02-23       Impact factor: 3.012

7.  Evaluation of a Pharmacokinetic Interaction between Telmisartan and Chlorthalidone in Healthy Male Adult Subjects.

Authors:  Sook Jin Seong; Mi-Sun Lim; Joomi Lee; Boram Ohk; Mi-Ri Gwon; Bo Kyung Kim; Hyun-Ju Kim; Dong Heon Yang; Hae Won Lee; Woo Youl Kang; Young-Ran Yoon
Journal:  Clin Drug Investig       Date:  2016-08       Impact factor: 2.859

8.  Triple combination therapy in hypertension: the antihypertensive efficacy of treatment with perindopril, amlodipine, and indapamide SR.

Authors:  Dénes Páll; Ildikó Szántó; Zoltán Szabó
Journal:  Clin Drug Investig       Date:  2014-10       Impact factor: 2.859

9.  Differential treatment of hypertension by primary care providers and hypertension specialists in a barber-based intervention trial to control hypertension in Black men.

Authors:  Florian Rader; Robert M Elashoff; Sara Niknezhad; Ronald G Victor
Journal:  Am J Cardiol       Date:  2013-08-23       Impact factor: 2.778

10.  Efficacy and safety of sacubitril/valsartan in patients with essential hypertension uncontrolled by olmesartan: A randomized, double-blind, 8-week study.

Authors:  Deanna G Cheung; Diego Aizenberg; Vladimir Gorbunov; Kudsia Hafeez; Chien-Wei Chen; Jack Zhang
Journal:  J Clin Hypertens (Greenwich)       Date:  2018-01-16       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.